Section Arrow
Quote
AUPH.NASDAQ
- Aurinia Pharmaceuticals
Quotes are at least 15-min delayed:2026/02/23 07:03 EST
Pre Market
Last
 14.55
+0.15 (+1.04%)
Bid
14.25
Ask
14.89
High 14.6 
Low 14.3 
Volume 99 
Regular Hours (Closed)
Last
 14.4
0 (0.00%)
Day High 
14.45 
Prev. Close
14.4 
1-M High
15.47 
Volume 
549.76K 
Bid
14.25
Ask
14.89
Day Low
14.12 
Open
14.39 
1-M Low
14.12 
Market Cap 
1.90B 
Currency 美元 
P/E 25.71 
%Yield -- 
10-SMA 14.39 
20-SMA 14.56 
50-SMA 15.18 
52-W High 16.54 
52-W Low 6.55 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
0.56/0.62
Enterprise Value
1.96B
Balance Sheet
Book Value Per Share
2.77
Cash Flow
Cash Flow Yield
0.06
Income Statement
Total Revenue
318.00K
Operating Revenue Per Share
1.20
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
CDIOCardio Diagnostics Holdings Inc.2.88+0.64+28.57%-- 
Pre Market 2.88 0 0.00%
IBRXImmunityBio8.7+0.09+1.05%-- 
Pre Market 8.61 -0.09 -1.03%
GERNGeron Corp1.88-0.04-2.08%-- 
Pre Market 1.83 -0.05 -2.66%
QNCXQuince Therapeutics0.1501-0.0121-7.46%-- 
Pre Market 0.1504 +0.0003 +0.20%
RXRXRecursion Pharmaceuticals3.42-0.3-8.06%-- 
Pre Market 3.37 -0.05 -1.46%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmunediseases.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.